Related Experiment Video
Updated: May 21, 2026

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
[Animal models of human glioma: the progress of application and investigation]
Hui-Fang Zhu1, Yuan-Xu Zhang, Xu-Dong Zhao
1Chinese Academy of Science, Kunming, China.
Abstract:
The glioma accounts for half of the central nervous tumors, among which the glioblastoma multiforme (GBM) is one of the most aggressive and lethal brain tumors. The difficulties in glioma therapy indicate the need of appropriate animal models for preclinical studies. Benefiting from the development of molecular biology, genetics, and transgenic technology, variable animal models of glioma have been established. These animal models of human glioma are reviewed in this paper.
Insights
Glioma, a common brain tumor, presents therapeutic challenges. This review covers various animal models crucial for advancing glioma research and preclinical studies.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Translational Medicine
Context:
- Glioma represents 50% of central nervous system tumors.
- Glioblastoma multiforme (GBM) is a highly aggressive and lethal brain tumor.
- Therapeutic challenges necessitate effective preclinical models.
Purpose:
- To review established animal models for human glioma.
- To highlight advancements in molecular biology, genetics, and transgenic technologies for model development.
- To provide a resource for selecting appropriate models for glioma research.
Summary:
- This paper reviews various animal models developed for studying human glioma.
- These models leverage advancements in molecular biology, genetics, and transgenic technologies.
- The review focuses on models suitable for preclinical studies of glioma and glioblastoma multiforme.
Impact:
- Facilitates the selection of appropriate animal models for glioma research.
- Aids in the development of novel therapeutic strategies for brain tumors.
- Supports preclinical testing and validation of new glioma treatments.
